无创高频振荡通气作为极早产儿主要呼吸支持:多中心随机对照试验
该多中心随机对照试验在中国20个三级新生儿重症监护病房纳入342例胎龄24周+0天至28周+6天的极早产儿呼吸窘迫综合征患儿,随机接受无创高频振荡通气或鼻持续气道正压通气作为主要呼吸支持。主要终点为出生后72小时内需有创机械通气,无创高频振荡通气组15.9%(27/170)低于鼻持续气道正压通气组27.9%(48/172),风险差-12.0个百分点(95%CI -20.7至-3.4,P=0.007)。7天内治疗失败率也较低(风险差-12.5个百分点,95%CI -21.9至-3.2,P=0.008)。两组其他次要结局及新生儿不良事件无显著差异。
要点
- 极早产儿(胎龄24周+0天至28周+6天)呼吸窘迫综合征以无创高频振荡通气作主要支持,72小时内插管率15.9%(27/170)低于鼻持续气道正压通气27.9%(48/172),风险差-12.0个百分点(95%CI -20.7至-3.4,P=0.007)。
- 7天内治疗失败率无创高频振荡通气组较鼻持续气道正压通气组低12.5个百分点(95%CI -21.9至-3.2,P=0.008)。
- 敏感性分析纳入研究中心和产前激素使用后,观察到的关联仍显著。
- 两组其他次要结局及新生儿不良事件无显著差异。
- 作者结论认为无创高频振荡通气作为极早产儿主要呼吸支持策略在减少插管需求方面似乎优于鼻持续气道正压通气。
适用人群与场景
- 胎龄24周+0天至28周+6天的极早产儿,诊断为呼吸窘迫综合征,需要主要呼吸支持。
- 研究在中国20个三级新生儿重症监护病房进行,纳入时间为2022年8月至2024年8月。
处置流程与药物剂量
- 无创高频振荡通气或鼻持续气道正压通气作为呼吸窘迫综合征的主要呼吸支持,随机分配。
研究设计与关键结果
- 多中心随机对照试验,342例极早产儿,随机接受无创高频振荡通气(n=170)或鼻持续气道正压通气(n=172)。
- 主要终点出生后72小时内需有创机械通气:无创高频振荡通气组27/170(15.9%)vs 鼻持续气道正压通气组48/172(27.9%),风险差-12.0个百分点(95%CI -20.7至-3.4;P=0.007)。
- 7天内治疗失败:无创高频振荡通气组较鼻持续气道正压通气组风险差-12.5个百分点(95%CI -21.9至-3.2;P=0.008)。
- 敏感性分析纳入研究中心和产前激素使用后,所有观察到的关联仍显著。
- 两组其他次要结局无显著差异。
- 两组新生儿不良事件无显著差异。
证据类型、等级与局限
- 多中心随机对照试验。
- 试验注册号:ClinicalTrials.gov NCT05141435。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于胎龄24周+0天至28周+6天的极早产儿呼吸窘迫综合征,以无创高频振荡通气作为主要呼吸支持可减少72小时内及7天内插管需求,作者结论认为无创高频振荡通气似乎优于鼻持续气道正压通气。
- 两组新生儿不良事件无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To test the hypothesis that non-invasive high frequency oscillatory ventilation (NHFOV) is more efficacious than nasal continuous positive airway pressure (NCPAP) in reducing invasive mechanical ventilation as primary respiratory support for extremely preterm infants with respiratory distress syndrome.
DESIGN: A multicentre, randomised controlled trial.
SETTING: Twenty tertiary neonatal intensive care units in China.
PARTICIPANTS: 342 extremely preterm infants (gestational age between 24 weeks +0 day and 28 weeks +6 days) with respiratory distress syndrome were enrolled in the study between August 2022 and August 2024.
INTERVENTIONS: Participants were randomly allocated to receive NCPAP or NHFOV as primary respiratory support for respiratory distress syndrome.
MAIN OUTCOME MEASURES: The primary outcome was treatment failure, defined as the need for invasive mechanical ventilation within 72 hours after birth.
RESULTS: Treatment failure within 72 hours occurred in 27 of` 170 infants (15.9%) in the NHFOV group and 48 of 172 infants (27.9%) in the NCPAP group (risk difference -12.0 percentage points, 95% confidence interval -20.7 to -3.4; P=0.007). Treatment failure within seven days was also lower in the NHFOV group (-12.5 percentage points, 95% confidence interval -21.9 to -3.2; P=0.008) compared with the NCPAP group. All observed associations remained significant after sensitivity analysis including study sites and antenatal steroid use. No significant differences were found in any other secondary outcomes between the two groups.
CONCLUSIONS: NHFOV appeared superior to NCPAP in reducing the need for intubation when used as a primary respiratory support strategy in extremely preterm infants. Both techniques did not show significant differences in neonatal adverse events.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05141435.
参考来源
- Li Y, Zhu X, Li LJ, et al. Non-invasive high frequency oscillatory ventilation for primary respiratory support in extremely preterm infants: multicentre randomised controlled trial. BMJ. 2025. PMID: 41052898. doi:10.1136/bmj-2025-085569
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。